Pieris Pharmaceuticals to Host First Quarter 2019 Investor Call and Corporate Update on May 10, 2019

May 3, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / May 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2019 investor call on Friday, May 10, 2019 at 8:00 AM (EDT) to discuss financial results and provide a corporate update. To access...

Read more

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.

May 2, 2019 7:05 AM

Represents key appointment to bolster scientific and oncology expertise as Company prepares to advance XCART platform technology Internationally renowned expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with autologous and allogeneic stem cell transplantations Pioneer in developing specific donor-derived immune cells FRAMINGHAM, MA / ACCESSWIRE / May...

Read more

Pressure BioSciences Announces CEO Succession Plan

May 1, 2019 9:29 AM

Richard T. Schumacher to Step Down as President & CEO on September 9, 2019; Will Remain as Senior Consultant to Support Leadership Transition SOUTH EASTON, MA / ACCESSWIRE / May 1, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that Mr....

Read more

Hancock Jaffe Announces Successful Third Implantation for CoreoGraft Study at Texas Heart Institute

May 1, 2019 8:31 AM

All Three Test Subjects for the Feasibility Study Have Now Been Successfully Implanted IRVINE, CA / ACCESSWIRE / May 1, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced the successful third implantation of its CoreoGraft® pre-clinical feasibility study at the Texas Heart Institute. Bypasses using the CoreoGraft have now been successfully...

Read more

Vitro Biopharma Receives ISO 13485 Certification Supporting its Stem Cell Medical Tourism Initiative

April 30, 2019 2:30 PM

GOLDEN, CO / ACCESSWIRE / April 30, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma one of the world's emerging biotechnology companies focused on allogeneic Mesenchymal Stem Cell ("MSC") research and clinical products including AlloRx Stem Cells™, Brain Grow Technologies™ NutraVivo™ Stem Cell Activator, and the MSC-Gro™ Brand Stem Cell Culture Media has been awarded Certification to the International Organization for...

Read more

HemaGenetics Announces Completion of the Plan of Arrangement with 1169082 B.C. Ltd.

April 30, 2019 12:19 PM

VANCOUVER, BC / ACCESSWIRE / April 30, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the Company...

Read more

Hancock Jaffe Mourns the Loss of Director Marc Robins

April 30, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / April 30, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announces the passing of its director, Marc Robins. Mr. Robins passed away from complications from chronic venous insufficiency. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, ''It is ironic that Marc lost his life to the same disease that our VenoValve is...

Read more

Dyadic Announces Sub-Licensing Agreement with Luina Bio

April 30, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / April 30, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, is pleased to announce it has entered into a worldwide...

Read more

ZIVO To Hold Its Annual Meeting May 1, 2019 at the Detroit Athletic Club

April 29, 2019 9:20 AM

KEEGO HARBOR, MI / ACCESSWIRE / April 29, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company will hold the Annual Meeting of shareholders of Zivo Bioscience, Inc. on May 1, 2019 at The Detroit Athletic Club, 241 Madison Street, Detroit, Michigan 48226, on Wednesday, May 1, 2019 at 10:00 a.m. local time. The Definitive Proxy Statement announcing the Annual Meeting was filed with the United States Securities and...

Read more

Mymetics Receives Funding from NIH for Novel HIV Vaccine Study

April 29, 2019 8:00 AM

Funding to prepare Mymetics' cold chain-independent needle-free mucosal virosome HIV vaccine candidate for clinical trials Collaboration with Texas Biomedical Institute and University of Louisiana at Lafayette Total award USD 8.67 million over 5 years, with USD 1.9 million budget in the first year EPALINGES, SWITZERLAND / ACCESSWIRE / April 29, 2019 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and...

Read more

HemaGenetics Announces Setting of the Effective Date for the Plan of Arrangement with 1169082 B.C. Ltd.

April 26, 2019 4:13 PM

VANCOUVER, BC / ACCESSWIRE / April 26, 2019 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the "Arrangement"), the...

Read more

Dyadic to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

April 25, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / April 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for...

Read more

ORYZON to Present Vafidemstat Efficacy Data at the 7th World Congress on ADHD in Lisbon

April 25, 2019 12:00 PM

Efficacy data from the REIMAGINE Phase IIa basket trial's Attention Deficit Hyperactivity Disorder (ADHD) cohort Second positive report of vafidemstat in a human CNS indication Company announces decision to pursue further development of vafidemstat in psychiatric indications MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / April 25, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage...

Read more

Pressure BioSciences, Inc. Reports Record Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

April 25, 2019 10:56 AM

Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High; FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High; Initial Revenue Reported from New BioPharma Services and UST Businesses; Balance Sheet Improves with Significant Conversion of Debt to Equity. Investor Conference Call Scheduled for Thursday, April 25, 2019 at 4:30 PM EDT SOUTH EASTON, MA / ACCESSWIRE /...

Read more

Avalon GloboCare Announces $6 Million Registered Direct Offering with Institutional Investors

April 25, 2019 8:58 AM

FREEHOLD, NJ / ACCESSWIRE / April 25, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has entered into a purchase agreement with several institutional investors for the purchase of 1,714,288 units in a registered direct offering, for expected gross proceeds of approximately $6 million before placement agent fees and other offering expenses payable by the...

Read more

Oncolytics Biotech(R) Announces Details of 2019 Annual General Meeting of Shareholders

April 25, 2019 7:00 AM

CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its Annual General Meeting of Shareholders will be held on Thursday, May 2nd, 2019 at 4:00 pm ET at Vantage Venues (formerly St. Andrew's Club & Conference Center) located at 150 King St. West, 27th Floor, Toronto,...

Read more

Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2018 Financial Results and Provide Business Update

April 24, 2019 9:52 AM

Conference Call Scheduled for Thursday, April 25th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by...

Read more

Eminent M.I.T. Institute Professor, Robert S. Langer, Sc.D., Joins Avalon GloboCare's Scientific and Clinical Advisory Board

April 24, 2019 8:00 AM

MIT's David H. Koch Institute Professor; world-renowned scientist and bio-entrepreneur Anticipating collaborative projects with Avalon FREEHOLD, NJ / ACCESSWIRE / April 24, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Robert S. Langer, Sc.D., to its Scientific and Clinical Advisory Board. Dr. Robert S. Langer is...

Read more

Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 23, 2019 7:00 AM

CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 2019 Bloom Burton & Co. Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 11:00 am ET, on Tuesday, April 30, 2019, at the Metro Toronto Convention...

Read more

Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market

April 18, 2019 9:25 AM

Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market HONG KONG / ACCESSWIRE / April 18, 2019 / A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries, referred to as the "Group"; Stock code: 0690.HK), is...

Read more